NEW YORK CITY, NY / ACCESS Newswire / May 31, 2025 / WHY: New York, N.Y., May 31, 2025. Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the period from October 11, […]

Flex (NASDAQ: FLEX) has announced members of its leadership team will participate in the upcoming investor conference: Bank of America 2025 Global Technology Conference Date:June 4, 2025Presentation time: 1:20pm PT / 4:20pm ET The presentation will be available as a live webcast accessible through the Flex Investor Relations website athttps://investors.flex.com. An archived replay will be

NEW YORK CITY, NY / ACCESS Newswire / May 31, 2025 / WHY: New York, N.Y., May 31, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Everus Construction Group, Inc. (NYSE:ECG) between October 31, 2024 and February 11, 2025, both dates inclusive (the "Class Period"), including investors

NEW YORK CITY, NY / ACCESS Newswire / May 31, 2025 / WHY: New York, N.Y., May 31, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ:VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), of the important June 3,

(NasdaqGM:ACTU), Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP Data featured as

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer GlobeNewswire May 31, 2025 Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival

Hundreds united to support life-saving cancer research and create a world freefrom thefearofcancer More than 400 cricketers gathered at Celebration Square as The Princess Margaret Cancer Foundation (The PMCF), presented by TD, hosted the inaugural Cricket to Conquer Cancer- the largest street cricket fundraiser in Canada. This landmark eventsignalled a major moment in Canada's evolving

(NASDAQ:GOCO), NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GoHealth, Inc. (NASDAQ: GOCO) resulting from allegations that GoHealth may have issued materially misleading business information to the investing public. SO WHAT: If you purchased

GoHealth, Inc. Investor News: If You Have Suffered Losses in GoHealth, Inc. (NASDAQ: GOCO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights GlobeNewswire May 31, 2025 NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on

NEW YORK CITY, NY / ACCESS Newswire / May 31, 2025 / WHY: New York, N.Y., May 31, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation (NASDAQ:DMRC) between May 3, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), of the important July 8,